Eli Rosenbaum
Papers
1
Total Citations
37
H-Index
1
About
Eli Rosenbaum is a pioneering clinical researcher in theranostics and urologic oncology, with a primary focus on advancing radionuclide therapy for prostate cancer. His most impactful work centers on the preoperative use of 177Lu-PSMA-I&T, a targeted radioligand therapy, in patients with high-risk prostate cancer. In his landmark single-arm Phase 1 trial, Rosenbaum demonstrated the feasibility and safety of neoadjuvant 177Lu-PSMA treatment before radical prostatectomy, achieving 37 citations and establishing a novel paradigm for integrating molecular radiotherapy into the surgical treatment pathway. This contribution is particularly significant as it explores how systemic radionuclide therapy can downstage aggressive tumors prior to surgery, potentially improving long-term outcomes. Rosenbaum’s research bridges nuclear medicine and surgical oncology, offering a precision-medicine approach to one of the most challenging prostate cancer presentations. His work has been recognized for its translational impact, directly influencing clinical trial design and opening avenues for larger, randomized studies. For students and researchers, Rosenbaum exemplifies how innovative theranostic strategies can reshape standard-of-care protocols in high-risk malignancies.
Research Focus
Key Achievements
Top Papers
- 1